Longevity & AgingStem Cell Beta Cells Restore Insulin Independence in Type 1 Diabetes Trials
A comprehensive 2025 review in Diabetes journal traces the evolution of islet cell replacement therapy for type 1 diabetes (T1D). Phase 3 trials of deceased donor islet transplantation demonstrated that 87.5% of high-risk recipients achieved HbA1c below 7% without severe hypoglycemia at one year. Breakthrough stem cell–derived beta cells (SC-β-cells) have now restored insulin independence in immunosuppressed T1D recipients in early clinical trials. Long-term follow-up of over 255 transplant patients showed 79% achieved insulin independence and 70% maintained graft function over a median 7.4 years. The review highlights parallel strategies to eliminate chronic immunosuppression, including immune-isolating encapsulation devices, engineered immune-privileged implantation sites, immune-evasive cell engineering, and tolerance induction protocols, all approaching or already in clinical investigation.
